Ginkgo Bioworks Holdings Debt to Equity Ratio 2020-2023 | DNA
Current and historical debt to equity ratio values for Ginkgo Bioworks Holdings (DNA) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Ginkgo Bioworks Holdings debt/equity for the three months ending March 31, 2023 was 0.00.
| Ginkgo Bioworks Holdings Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2023-03-31 |
$0.81B |
$1.61B |
0.50 |
| 2022-12-31 |
$0.80B |
$1.74B |
0.46 |
| 2022-09-30 |
$0.43B |
$1.44B |
0.30 |
| 2022-06-30 |
$0.43B |
$1.57B |
0.27 |
| 2022-03-31 |
$0.44B |
$1.61B |
0.28 |
| 2021-12-31 |
$0.50B |
$1.57B |
0.32 |
| 2021-09-30 |
$0.53B |
$1.62B |
0.33 |
| 2021-06-30 |
$1.72B |
$0.01B |
344.20 |
| 2021-03-31 |
$1.72B |
$0.01B |
344.59 |
| 2020-12-31 |
$0.00B |
|
0.00 |
| 2020-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2019-12-31 |
$0.00B |
$0.00B |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$3.608B |
$0.478B |
|
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
|
